European Commission approves Dzuveo to manage acute moderate to severe pain in medically monitored settings.- AcelRx Pharmaceuticals Inc.
AcelRx Pharmaceuticals, Inc. announced that the European Commission (EC) has approved Dzuveo (under development in the U.S. as Dsuvia) for the management of acute moderate to severe pain in adults in medically monitored settings. Dzuveo represents the second EC approval for an AcelRx developed product, with the first being Zalviso which is currently being marketed in Europe by Gr�nenthal.
AcelRx previously announced the acceptance of the resubmitted New Drug Application for Dsuvia (approved in Europe as Dzuveo by the FDA for which the FDA has assigned a PDUFA (Prescription Drug User Fee Act) date of November 3, 2018.
Related news and insights
Zai Lab Limited and its partner Entasis Therapeutics Holdings Inc. announced topline results from the ATTACK trial, a global Phase III registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
Atea Pharmaceuticals, Inc. reported that the global Phase II MOONSONG trial evaluating AT 527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population, of which approximately two thirds of patients were low-risk with mild symptoms.